Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease ...

ProMIS Neurosciences (PMN) announced important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its ...

elegans and mammalian neuronal cultures (Fonte et al, 2011). We propose that a primary mechanism of Abeta toxicity is the formation of membrane-damaging oligomers, which is blocked by the G37L ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that damage brain cells.

Yet as the different pathological roles of distinct Aβ species have become clearer, the possibility of selectively targeting specific types of Aβ, as with ACU193’s targeting of Aβ oligomers ...

In diseases like Parkinson's and Alzheimer's, specific proteins misfold and clump together, forming toxic aggregates that damage brain ...

Alfa Chemistry has made a remarkable stride in the field of synthetic biology with the recent renewal of its oligonucleotide series products. This updated lineup includes a range of advanced ...